ATE140267T1 - Screening-verfahren für protein-inhibitoren und - aktivatoren. - Google Patents

Screening-verfahren für protein-inhibitoren und - aktivatoren.

Info

Publication number
ATE140267T1
ATE140267T1 AT89902686T AT89902686T ATE140267T1 AT E140267 T1 ATE140267 T1 AT E140267T1 AT 89902686 T AT89902686 T AT 89902686T AT 89902686 T AT89902686 T AT 89902686T AT E140267 T1 ATE140267 T1 AT E140267T1
Authority
AT
Austria
Prior art keywords
protein
cli
substance
phenotypic
clii
Prior art date
Application number
AT89902686T
Other languages
English (en)
Inventor
Gerard M Housey
Original Assignee
Gerard M Housey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22550430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE140267(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gerard M Housey filed Critical Gerard M Housey
Application granted granted Critical
Publication of ATE140267T1 publication Critical patent/ATE140267T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT89902686T 1988-02-10 1989-02-09 Screening-verfahren für protein-inhibitoren und - aktivatoren. ATE140267T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/154,206 US4980281A (en) 1988-02-10 1988-02-10 Method of screening for protein inhibitors and activators

Publications (1)

Publication Number Publication Date
ATE140267T1 true ATE140267T1 (de) 1996-07-15

Family

ID=22550430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89902686T ATE140267T1 (de) 1988-02-10 1989-02-09 Screening-verfahren für protein-inhibitoren und - aktivatoren.

Country Status (18)

Country Link
US (1) US4980281A (de)
EP (1) EP0403506B1 (de)
JP (1) JPH03503598A (de)
AT (1) ATE140267T1 (de)
AU (1) AU612948B2 (de)
BG (1) BG60325B2 (de)
CA (1) CA1334927C (de)
DE (1) DE68926816T2 (de)
DK (2) DK189590A (de)
ES (1) ES2010131A6 (de)
FI (1) FI102618B1 (de)
HU (1) HU208555B (de)
IE (1) IE77332B1 (de)
IL (1) IL89227A (de)
MX (1) MX165993B (de)
NO (2) NO313103B1 (de)
RO (1) RO118452B1 (de)
WO (1) WO1989007654A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
EP0528827B1 (de) * 1990-04-19 1996-09-04 The General Hospital Corporation Screening nach proteinpartnern und deren verwendung
US5322801A (en) * 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
US6080540A (en) * 1990-04-20 2000-06-27 Cold Spring Harbor Laboratory Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
FI931268L (fi) * 1990-09-24 1993-04-21 Gen Hospital Corp Saollningsfoerfaranden
US5707810A (en) * 1991-03-11 1998-01-13 Creative Biomolecules, Inc. Method of diagnosing renal tissue damage or disease
US5650276A (en) * 1991-03-11 1997-07-22 Creative Biomolecules, Inc. Morphogenic protein screening method
ATE250629T1 (de) * 1991-04-19 2003-10-15 Univ Washington Für säugetierphosphodiesterasen kodierende dns
US5747341A (en) * 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
EP0605428B9 (de) * 1991-06-24 2003-01-02 hCell Technology, Inc. In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
US5821121A (en) * 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
WO1993002209A1 (en) * 1991-07-22 1993-02-04 The Regents Of The University Of California Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
AU696364B2 (en) * 1991-08-30 1998-09-10 Creative Biomolecules, Inc. Morphogenic protein screening method II
EP0825442A3 (de) * 1991-08-30 2004-02-11 Curis, Inc. Screeningverfahren von morphogenischen Proteinen
GB9216654D0 (en) * 1992-08-05 1992-09-16 Imp Cancer Res Tech Transformed cells and assays using them
US6048850A (en) * 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5837479A (en) * 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
DE4306547C2 (de) * 1993-03-03 1996-07-11 Gsf Forschungszentrum Umwelt In-vitro-Test zur Detektion von Proteinkinase C Inhibitoren
JPH09501302A (ja) * 1993-04-07 1997-02-10 キャンサー リサーチ キャンペーン テクノロジー リミティド 治療活性についての物質のスクリーニングのための方法及びそれにおいて利用するための方法
US5776685A (en) * 1993-07-19 1998-07-07 Joslin Diabetes Center Protein kinase C assay
JPH09510104A (ja) * 1994-03-10 1997-10-14 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 形質転換の進行の誘導性阻害剤を同定する方法
DE69532127T2 (de) 1994-07-20 2004-08-26 Genetics Institute, Inc., Cambridge Interaktions-fullensysteme zum nachweis von protein-interaktionen
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5597697A (en) * 1994-09-30 1997-01-28 Diamond; Paul Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases
KR100402836B1 (ko) * 1995-05-11 2004-02-19 주식회사 엘지생명과학 단백질간의상호작용을조절하는물질의새로운탐색시스템
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
DK0877752T3 (da) 1996-01-23 2003-09-15 Univ Leland Stanford Junior Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
AU724107B2 (en) * 1997-01-31 2000-09-14 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin E
US7507705B2 (en) 1997-10-02 2009-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
WO1999024563A1 (en) 1997-11-07 1999-05-20 Iconix Pharmaceuticals, Inc. Surrogate genetics target characterization method
PL340433A1 (en) 1997-11-10 2001-02-12 Gen Hospital Corp Detection systems for detecting and recording protein-specific actions and functional interactions
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6518035B1 (en) 1998-06-02 2003-02-11 Rosetta Inpharmatics, Inc. Targeted methods of drug screening using co-culture methods
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US6589738B1 (en) 1999-11-09 2003-07-08 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation and antisense thereto
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
CA2408743A1 (en) * 2000-05-25 2001-11-29 Curagen Corporation Method of detecting inflammatory lung disorders
WO2002000933A2 (en) * 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20030170694A1 (en) * 2001-12-21 2003-09-11 Daniel Wall Stabilized nucleic acids in gene and drug discovery and methods of use
WO2003099222A2 (en) * 2002-05-23 2003-12-04 Invitrogen Corporation Pseudo-tissues and uses thereof
WO2004011496A2 (en) 2002-07-04 2004-02-05 Nalan Utku Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
WO2004020666A2 (en) * 2002-09-02 2004-03-11 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases
US20050214292A1 (en) * 2002-10-18 2005-09-29 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20040191818A1 (en) * 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
JP2007537984A (ja) * 2003-03-04 2007-12-27 ワイス 喘息または他のアレルギー性もしくは炎症性疾患の診断および治療のための組成物および方法
EP1620564A4 (de) * 2003-04-18 2008-03-12 Cytovia Inc Verfahren zur behandlung von auf apoptoseinduktion reagierenden krankheiten und screening-tests
US20050119210A1 (en) * 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
WO2005020902A2 (en) * 2003-08-21 2005-03-10 Cytokine Pharmasciences, Inc. Compositions and methods for treating and diagnosing irritable bowel syndrome
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
EP3461813A1 (de) * 2004-05-23 2019-04-03 Gerard M. Housey Theramuteinmodulatoren
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
CN103789389B (zh) 2005-11-23 2017-01-04 杰勒德·M·豪斯 鉴定、合成、优化和表征蛋白调节剂的化合物和方法
EP1878744A1 (de) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren
US20090285819A1 (en) * 2006-11-15 2009-11-19 Functional Genetics, Inc. Methods and compositions for treating influenza

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4480038A (en) * 1982-04-30 1984-10-30 E. I. Dupont De Nemours And Company Density separation of protein overproducing bacteria
US4532204A (en) * 1982-07-19 1985-07-30 Massachusetts Institute Of Technology Mutation assays involving blood cells that metabolize toxic substances
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators

Also Published As

Publication number Publication date
JPH03503598A (ja) 1991-08-15
CA1334927C (en) 1995-03-28
DE68926816T2 (de) 1997-01-09
US4980281A (en) 1990-12-25
FI903918A0 (fi) 1990-08-08
EP0403506B1 (de) 1996-07-10
IL89227A0 (en) 1989-09-10
FI102618B (fi) 1999-01-15
HU208555B (en) 1993-11-29
NO20021142L (no) 1990-10-01
NO20021142D0 (no) 2002-03-07
DK189590D0 (da) 1990-08-09
DK189590A (da) 1990-10-02
MX165993B (es) 1992-12-15
DE68926816D1 (de) 1996-08-14
NO903494L (no) 1990-10-01
AU612948B2 (en) 1991-07-18
WO1989007654A1 (en) 1989-08-24
EP0403506A4 (en) 1991-07-24
ES2010131A6 (es) 1989-10-16
AU3184089A (en) 1989-09-06
IE890398L (en) 1989-08-10
IE77332B1 (en) 1997-12-02
NO903494D0 (no) 1990-08-08
FI102618B1 (fi) 1999-01-15
DK200100720A (da) 2001-05-08
RO118452B1 (ro) 2003-05-30
HUT55447A (en) 1991-05-28
EP0403506A1 (de) 1990-12-27
IL89227A (en) 1995-05-26
BG60325B2 (bg) 1994-05-27
NO313103B1 (no) 2002-08-12

Similar Documents

Publication Publication Date Title
ATE140267T1 (de) Screening-verfahren für protein-inhibitoren und - aktivatoren.
Matsunaga et al. Rapid determination of nicotinic acid by immobilized Lactobacillus arabinosus
ES8609459A1 (es) Procedimiento para la preparacion de pelicula de celulosa
FR2543158B1 (fr) Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
DK0516817T3 (da) Fremgangsmåde og medium til detektion af Salmonella
ES8802471A1 (es) Un procedimiento para la produccion de una preparacion de activador de proteina c.
KR880007714A (ko) 구군 식물의 증식방법
Fukumoto et al. Effects of carbon sources and base analogues of nucleic acid on the formation of bacterial amylase
PT1248852E (pt) Metodo de avaliacao de viabilidade de uma celula
ES8504245A1 (es) Procedimiento para la obtencion de sarcosin-oxidasa
DE60140526D1 (de) Herstellung von tcr gamma delta t-zellen
Höfle Transient responses of glucose-limited cultures of Cytophaga johnsonae to nutrient excess and starvation
DE3871530D1 (de) Vorrichtung zum kultivieren von ruhenden zellen in einem bioreaktor.
ATE132896T1 (de) Methoden zur verwendung von an humanen klasse-ii- histokompatibilitätsantigenen mangelnden zellinien
ATE5199T1 (de) Verfahren zur gewinnung von glucosedehydrogenase und hierfuer geeignete mikroorganismen.
ATE280837T1 (de) Verfahren zum screening von mikroorganismen unter nährstofflimitierten bedingungen
ATE420363T1 (de) Methode zur detektion von salmonella aus vorkulturen
DE69014723D1 (de) Zellzüchtungsverfahren.
CA2267655A1 (en) Assay using marked microbial host cell strains
Pandey Interdependence of glucose and arginine catabolism in Streptococcus faecalis R. ATCC 8043
ATE231614T1 (de) Screening-test für kalium-kanal agonisten
SU136092A1 (ru) Способ обнаружени углеводородной микрофлоры
SU1445398A1 (ru) Способ определения температурной устойчивости микроорганизмов
Islands Acoustic and Telephone Measurements
KR840002454A (ko) 심부배양을 위한 세포 클로운의 자동 선별 방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
RZN Patent revoked